Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional StudyHiroki Ishihara, Toshio Takagi, Yuki Nemoto et al.|Targeted Oncology|2023Cited by 19
Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinomaYuki Nemoto, Toshio Takagi, Hiroki Ishihara et al.|International Urology and Nephrology|2021Cited by 18
Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumabMaki Yoshino, Toshio Takagi, Yasunobu Hashimoto et al.|Japanese Journal of Clinical Oncology|2022Cited by 16
Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinomaHiroki Ishihara, Toshio Takagi, Tsunenori Kondo et al.|Japanese Journal of Clinical Oncology|2021Cited by 15
Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor EraHiroki Ishihara, Toshio Takagi, Yuki Nemoto et al.|Targeted Oncology|2022Cited by 10